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Abstract
The aim of the study was to evaluate the effectiveness of ribonucleic acid in the correction of immune disorders in patients 
with infectious mononucleosis (IM) caused by EBV.
Materials and methods. We examined 110 patients with a mean age of 23.3 ± 4.2 years with IM, among whom women ac-
counted for 52.7 % (n = 58). The material for the study was the serum of patients obtained during the disease course. The set of tests 
of patients with IM included clinical and biochemical methods, enzyme-linked immunosorbent assay, polymerase chain reaction 
method, immunogram. Statistical processing of the obtained data was performed with «Statsoft Statistica v. 10.0 for Windows» using 
the methods of variation and correlation statistics.
Results. The obtained results analysis revealed changes in the system of cellular and humoral parts of the immune system 
and the diversity of the immune response in patients with IM. The progressive nature of changes in immune parameters indicated 
the formation of secondary cellular immune imbalance, activation of the humoral link, a change in the balance of immunoregulatory 
mediators towards Th2 cells. Significant changes in the cellular immune system were observed in the acute period and were char-
acterized by the increase in the number of cells with killer activity, namely mature T-lymphocytes (CD3+), cytotoxic T-suppressor 
cells (CD8+), cells expressing the activation marker CD25+ (IL-2 receptor), and by the Th1/Th2 ratio increase. The appointment of 
combination therapy including ribonucleic acid was accompanied by immunomodulatory and antiviral effects, that was reflected 
in a more pronounced positive dynamics of immunological parameters, namely in strengthening the proliferative response, compared 
with the group of patients receiving only basic therapy.
Conclusion. The expediency of the combination therapy application: the drug Nuclex (ribonucleic acid) (250 mg) 2 capsules 
3 times a day for 14 days and valacyclovir (500 mg) at a dose of 1000 mg (2 tablets) 3 times a day for 14 days, is justified for the 
correction of immune disorders in patients with IM caused by EBV.









The study of the role of Epstein-Barr virus (EBV) infection in the occurrence of various 
pathological human conditions is of great importance [1, 2]. This is due to the significant epide-
miological role and social significance, as according to epidemiological data more than 90 % of 
people are already infected with EBV when they reach adulthood [3, 4]. The steady increase in the 
number of diseases caused by EBV in both adults and children, due to its specific tropism to immu-
nocompetent cells, lifelong persistence, and latent course, necessitates a comprehensive study and 
development of effective treatment methods [4].
It should be noted that for a long time EBV infection was associated exclusively with in-
fectious mononucleosis (IM), the clinical forms of which were most often registered among chil-
dren, but in recent years it is widespread among adults as well [5, 6]. Thus, over the past 10 years, 
the incidence of IM has increased 5 times, due to a real increase in morbidity because of vari-
ous exogenous and endogenous factors, and due to improved methods of laboratory diagnosis of 
this infection [5, 7].
Polymorphism of clinical manifestations of EBV infection is quite diverse and includes 
inapparent, manifest and chronic persistent forms. In clinical practice, possible clinical mani-
festations of some IM forms are associated with the disorders of the heart (myo-, endo- or peri-
carditis), endothelium (vasculitis), central and peripheral nervous system (meningitis, meningo-
encephalitis, mono- or polyradiculoneuritis), kidneys (nephritis), glandular organs (pancreatitis 
or orchitis), etc. in addition to the classical triad [8, 9]. EBV is currently associated with fever of 
unclear origin, several lymphoproliferative, oncological, demyelinating, neurological, autoim-
mune and other diseases [10, 11]. The presence of such variety of EBV infection clinical forms 
becomes clear when we consider EBV infection as an infectious disease with chronic persistence 
of the virus [5, 12, 13].
Prediction of the course and consequences of IM depends on individual viral factors, the 
severity of immune dysfunction, genetic predisposition to certain EBV-associated diseases and 
the influence of external factors (stress, infections, surgery, adverse environmental effects) that 
can damage the immune system [8, 14, 15]. The immune balance is not always restored after IM 
and changes in the hemogram persist for a long time [16–18].
Despite the progress made in the etiotropic therapy of other herpesvirus diseases, modern 
treatment strategies still lack the sufficiently advanced therapy for EBV infection, which would 
eliminate the persistent virus from the human body [11, 19]. Therefore, it is very important to 
conduct research to find effective treatment regimens that aim to rehabilitate the immune system, 
promote the regression of immune changes and complications and prevent recurrence in various 
forms of EBV infection.
The aim of the study was to evaluate the effectiveness of the drug Nuclex (ribonucleic acid) 
in the correction of immune disorders in patients with IM caused by EBV.
2. Materials and methods
The study was performed on the clinical basis of the Department of Infectious Diseases and 
Clinical Immunology of the School of Medicine of V. N. Karazin Kharkiv National University that 
is in the Department of differential diagnostics during 2017–2020 years, sore throats, neuroinfec-
tions of the Municipal Noncommercial Enterprise of Kharkiv Regional Council «Regional Clinical 
Infectious Diseases Hospital». Protocol No. 4, 14.03.2018, of the Bioethics Commission, School of 
Medicine of V. N. Karazin National University.
The inclusion criteria were:
1) age of patients from 18 to 52 years;
2) the presence of clinical manifestations of EBV infection;
3) etiological confirmation of the disease with markers of replicative activity of EBV (sero-
logical and/or molecular genetic research methods);
4) informed voluntary consent to participate in the study.
The study adhered to the tenets of the World Medical Association Declaration of Helsinki, 
the Code of Ethics of Physicians of Ukraine, informing the patient about the nature of the study. 
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The clinical diagnosis in our patients was defined as B27 according to the Tenth Revision of the 
International Statistical Classification of Diseases and Related Health Problems (2007 version). 
Verification of the clinical diagnosis of IM was performed in accordance with the recommenda-
tions of J. I. Vozianova et al. (2001). The severity and features of mononucleosis-like syndrome 
were evaluated, considering the presence of concomitant pathology.
110 patients (47.3 % (52 mans) 52.7 % (58 women)) with moderate to severe IM were exam-
ined in our study. The mean age of patients was 23.3 ± 4.2 years. Patients with clinical manifesta-
tions of IM were divided in two groups based on the therapy regimen. The first group (n = 20) of 
patients was prescribed the combination therapy including Nuclex (250 mg) 2 capsules 3 times 
a day for 14 days as an immunomodulator and valacyclovir (500 mg) at a dose of 1000 mg (2 tablets) 
3 times a day for 14 days as an etiotropic antiviral therapy. The second group (n = 20) received 
only basic (antiviral) therapy. The control group consisted of 20 healthy young people. The effec-
tiveness of therapy in patients with EBV infection was evaluated based on clinical data and the 
rate of achieving biochemical, laboratory and virological remission (disappearance of EBV DNA 
or viremia reduction).
2. 1. Experimental procedures
The material for the study was the serum of patients with EBV infection. Blood samples 
were collected on an empty stomach from the ulnar vein in an amount of 10 ml in a sterile test 
tube type «Eppendorf».
Clinical blood tests, detection of atypical mononuclear cells, determination of specific im-
munoglobulin (Ig) to EBV by solid-phase enzyme-linked immunosorbent assay (ELISA), detection 
of EBV deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR) in blood and saliva were 
performed in all patients with IM during the disease. A set of serological and molecular genetic 
assays was used to confirm the diagnosis in addition to a general blood test. Heterophilic test in 
the modification of Goff-Bauer (Chireshkina N. M., 1973) was performed as a rapid diagnostic test 
to screen blood for the presence of EBV infection. 
Specific antiviral antibodies to EBV (VCA-IgM, EA-IgG and EBNA-IgG) in serum were 
detected by ELISA kits produced by «IBL» (Germany) and «Vector Best» (Russia) according to 
the instructions.
AmpliSens reagent kits (Russia) were used to detect EBV DNA by reverse transcription 
PCR with hybridization-fluorescence detection of amplification products. DNA isolation from the 
samples was performed using a DNA isolation kit from Miniprep (Silex M, Russia) using the me-
thod of DNA sorption on a sorbent by Boom R. et al., 1990. DNA amplification was performed 
using the DNA Amplification kit (Silex-M, Moscow) on the BIC amplifier. Genomic DNA was 
isolated using the «Kit for isolation of DNA/RNA from serum or plasma» (LitTech, Russia).
The results of the research were processed by the methods of variation and correlation sta-
tistics using the program «Statsoft Statistica v. 10.0 for Windows». The arithmetic mean (M), the 
standard deviation (σ), and the arithmetic mean error (m) were calculated for each variation series. 
Methods of parametric and nonparametric statistics were also used. Quantitative and qualitative 
analysis of intrasystem and intersystem correlations were performed using the method of correla-
tion structures and sequential Wald analysis.
3. Results
Hospitalization of patients was carried out from the 3rd to the 16th day of the disease, in most 
cases – from the 4th to the 11th day. On average, patients were hospitalized on the 8.3 ± 3.8 day 
of the disease.
Patients with IM underwent comprehensive treatment: ward, diet table No. 15, symptomatic 
therapy, namely detoxification, desensitizing, antipyretic drugs. They were prescribed antibac-
terial therapy in the presence of signs of activation of secondary infection, where the drugs of 
choice were mainly fluoroquinolones and cephalosporins (II–III generation). The duration of the 
course of antibacterial therapy averaged 6.4 ± 1.3 days. The need for antibacterial therapy arose in 
almost 70 % (n = 77) of IM cases.
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Clinical blood test results in most patients with IM showed an increased number of white 
blood cells (WBC) – from 5.6 to 28.3×109/L. A pronounced increase in lymphocytes during the 
disease was found in 99 patients (90 %) and lymphocytes did not exceed the normal value only 
in 11 patients (10 %). More than 1/3 of patients had monocytosis – 45 (40.9 %) patients, the per-
centage of monocytes was 11.4 ± 0.8 %. Pathological changes in the complete urinalysis (minor 
proteinuria, leukocyturia, cylindruria) were registered during the height of the disease in 50 % of 
IM patients (55 patients). There was an increase in alanine aminotransferase (ALT) (3–4 times 
higher than normal and averaged 2.5 ± 0.2 mmol/(g·l)) (p < 0.05) in patients with IM. All the 
above changes disappeared as the general condition of patients improved and biochemical 
parameters normalized.
Clinical signs indicating the activity of the viral infection of IM according to therapy regi-
men are presented in Table 1.
Table 1
Characteristics and duration of clinical symptoms in patients with IM using different treatment regimens 
(M ± m), days
Clinical symptoms 1st group (n = 20) 2nd group (n = 20)
Fever 12.2 ± 0.31 16.4 ± 0.7
Lymphadenopathy 16.3 ± 2.11 18.7 ± 1.5
General weakness 10.6 ± 0.51 14.7 ± 1.6
Enlargement of the tonsils 15.5 ± 1.4 16.6 ± 1.3




Sleep disorders 9.3 ± 0.4 10.5 ± 0.5
Nausea 5.7 ± 0.6 6.2 ± 0.4
Note: 1 – significant difference with the rates of patients receiving basic therapy (p < 0.05)
Analysis of the presented data in the table revealed that the longest clinical syndrome among 
patients with IM was lymphadenopathy syndrome, which was accompanied by the complaints 
of enlargement of the anterior and posterior lymph nodes. The duration of this syndrome was 
18.7 ± 5.5 days among patients receiving basic therapy, whereas in the group of patients receiving 
combination therapy it was 16.3 ± 2.1 days (p < 0.05). Also, manifestations of fever – 16.4 ± 0.7 ver-
sus 12.2 ± 0.3 days (p < 0.05); sore throat – 14.4 ± 0.7 versus 10.1 ± 0.4 (p < 0.05); hepato- and sple-
nomegaly – 18.5 ± 1.3 versus 14.8 ± 0.8 days and 16.6 ± 1.3 versus 13.5 ± 1.4 (p < 0.05) lasted signifi-
cantly longer in patients receiving basic therapy accordingly. The duration of astheno-vegetative 
syndrome in the form of general weakness was 14.7 ± 1.6 days in patients with basic therapy, while 
in the group of patients with combination therapy it lasted 10.6 ± 0.5 days (p < 0.05). Respiratory 
and lymphopharyngeal lesions in the form of pharyngitis and tonsillitis and other clinical manifes-
tations had no statistically significant differences between groups (p > 0.05).
Some positive changes in the immunogram parameters with a tendency to normalization of 
separate indicators were seen in patients with IM after the treatment (Table 2).
Analysis of changes of the main subpopulations of peripheral blood lymphocytes of pa-
tients with IM receiving combination therapy revealed a significant decrease in the absolute 
content of WBCs (p < 0.05), the relative content of CD4+, CD8+, CD16+, CD20+ lymphocytes 
and Th1/Th2 ratio (р < 0.05) compared with the results obtained in patients receiving basic 
therapy. It should be noted that the rate of the immunogram normalization was significantly 









Dynamics of the main subpopulations of peripheral blood lymphocytes in patients with IM depending on 
the therapy (M ± m)
Parameter Acute period of IM  before treatment (n = 40)
Basic therapy  
(n = 20)




WBC, 109/L 12.7 ± 0.82 7.35 ± 0.341, 3 5.38 ± 0.21, 2 5.37 ± 0.18
Lymphocytes, % 57.67 ± 2.81 38.65 ± 2.341, 3 33.39 ± 1.31 30.1 ± 1.75
Lymphocytes, 109/L 5.74 ± 0.65 3.6 ± 0.381 2.8 ± 0.21 2.55 ± 0.18
CD3+ cells, % 87.21 ± 3.34 69.2 ± 3.211 70.51 ± 2.31 65.85 ± 3.5
CD4+ cells, % 47.16 ± 1.07 44.1 ± 1.051 42.28 ± 1.11, 2 42.0 ± 1.31
CD8+ cells, % 44.16 ± 3.78 41.8 ± 2.231, 3 31.4 ± 2.11, 2 29.4 ± 1.9
CD16+ cells, % 16.61 ± 0.6 16.83 ± 0.63 13.95 ± 0.51, 2 14.52 ± 0.44
CD20+ cells, % 18.91 ± 0.9 17.67 ± 0.83 14.2 ± 0.31, 2 13.5 ± 0.5
СD25+ cells, % 21.40 ± 0.92 17.41 ± 0.631 15.4 ± 0.68 15.1 ± 0.65
Th1 (ІFNγ+), % 15.2 ± 0.94 12.3 ± 1.21 12.7 ± 0.61 11.1 ± 1.1
Th2 (IL-4+), % 10.4 ± 1.78 14.6 ± 1.351 13.5 ± 1.131 12.4 ± 1.43
Th1/Th2 1.46 ± 0.06 0.84 ± 0.05 0.94 ± 0.062 0.89 ± 0.09
Note: 1 – significant difference compared with indicators before treatment (p < 0.05; 2 – significant difference compared with the 
indicators of patients receiving basic therapy (p < 0.05); 3 – significant difference compared with the control group (p < 0.05)
4. Discussion
In our study, it was shown that the use of ribonucleic acid (Nuclex) in addition to vala-
cyclovir had a positive effect on the course of IM, namely, it significantly reduced the duration of 
clinical symptoms. It is noteworthy that there was not only a decrease in the duration of common 
manifestations of the infectious process, but also a significant reduction in the duration period of 
hepatomegaly and splenomegaly. Given recent data on the association of splenic rupture and altered 
liver function with IM, the use of Nuclex in the treatment of patients with IM may be effective in 
reducing the risk of complications of the spleen and liver [20–22]. Although our research involved 
both young and middle-aged patients, similar results were obtained in a study made by [23], that 
included only young patients aged from 18 to 25 years, most of whom were students [23].
It is known that the main target of EBV infection is B cells, but associations between EBV 
and T/NK cell lymphoproliferative diseases have also been widely discussed [12, 13, 18]. The ana-
lysis of the obtained results revealed changes in the system of cellular and humoral parts of the 
immune system and the diversity of the immune response in patients with IM. We found significant 
disorders of the сellular immunity in the acute period of IM. They included an increase in the num-
ber of cells with killer activity: mature T-lymphocytes (CD3+), cytotoxic T-suppressor cells (CD8+), 
cells expressing the activation marker CD25+ (receptor IL-2) and a sharp increase in Th1/Th2 ratio. 
The progressive nature of changes in immune parameters in case of IM indicates the formation of 
secondary cellular immune imbalance, activation of the humoral link and changes in the balance 
of immunoregulatory mediators towards Th2 cells. 
In this work, we showed that patients under the influence of complex immunomodulatory 
and antiviral action with the appointment of ribonucleic acid had more pronounced positive dyna-
mics of immunological alterations described above compared with patients who received only basic 
therapy and it was reflected through an increase in the proliferative response. The reason for such 
improvement in patients prescribed with combination therapy may be a specific antiviral activity of 
Nuclex, which is based on the mechanisms of influence on the surface antigens and virus receptors 
conformation, and its anti-inflammatory activity provided by regulation of adenosine Ade1 recep-
tor, normalization of NO-synthetase activity, stabilization of cell membranes and optimization of 
redox balance in tissues. Ribonucleic acid can also normalize cellular immunity by increasing the 
migration and cooperation of T- and B-lymphocytes and phagocytic activity of macrophages as 
well as by enhancing the activity of non-specific resistance factors, that also explains more pro-
minent changes in subpopulations of peripheral blood lymphocytes in our patients with IM using 
combination therapy compared to patients with IM using basic therapy [24, 25].
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Limitations of the study. During the study, the clinical, biochemical and immunological 
data of 110 patients with infectious mononucleosis were assessed, which is a sufficient reference 
sample. The study included adult patients with moderate to severe Epstein-Barr virus-associated 
infectious mononucleosis. The level of quality of life was not discussed.
Prospects for further research. Polymorphism of clinical manifestations and complica-
tions of IM necessitates the improvement of clinical and laboratory diagnosis and treatment strate-
gies for this disease. Therefore, studies evaluating the effectiveness of new therapy regimens with 
immunotropic drugs and their impact on the functional activity of immunocompetent cells are very 
relevant and promising.
5. Conclusions
The combination therapy including Nuclex and valacyclovir leads to a reduction in the dura-
tion of clinical symptoms among patients with IM compared with valacyclovir use only.
Addition of Nuclex to antiviral therapy with valacyclovir improves immunogram parame-
ters in patients with IM more effectively compared with valacyclovir use only.
The expediency of the combination therapy application, namely the drug Nuclex (ribo-
nucleic acid) (250 mg) 2 capsules 3 times a day for 14 days and valacyclovir (500 mg) at a dose of 
1000 mg (2 tablets) 3 times a day for 14 days, is justified for the correction of immune disorders 
in patients with IM caused by EBV.
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